touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • Choosing IOLs for patients with cataracts: Insights from an expert

    touchEXPERT OPINIONS for touchOPHTHALMOLOGY

    Listen to expert insights on how novel IOLs can address patients’ visual needs, the factors that influence IOL selection and managing patient expectations.

    The expert

    • Dr Rosa Braga-Mele - Professor of Ophthalmology, Faculty of Medicine at the University of Toronto, Canada.

    This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from Alcon Laboratories Inc. This activity is jointly provided by USF Health and touchIME.


    For further information visit our website: https://touchophthalmologyime.org/balancing-risks-and-benefits-of-intraocular-lens-options-for-cataract-surgery/

    32 min
  • Experts discuss the latest data for emerging HER2-directed therapies in advanced breast cancer

    touchPANEL DISCUSSION for touchONCOLOGY

    Listen as leading experts discuss the latest clinical data for emerging HER2-directed therapies and review novel therapeutic strategies and consider the implications for clinical practice.

    The experts

    • Dr Laura Biganzoli – Department of Oncology, Hospital of Prato, Prato, Italy
  • Dr Peter Fasching – Comprehensive Cancer Center, Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Dr Sonia Pernas – Catalan Institute of Oncology, and Faculty of Medicine, University of Barcelona, Barcelona, Spain

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent educational grant from SeaGen. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website:  https://touchoncologyime.org/expanding_options_her2_advanced_breast_cancer/

     

    34 min
  • Making the case for the MDT in NSCLC

    touchMDT for touchONCOLOGY

    Listen to a medical oncologist, a pathologist, a radiation oncologist and an oncology nurse practitioner discuss how to optimize treatment decisions, taking into account emerging therapies as well as patient expectations and preferences.

    The multidisciplinary team

    • Medical oncologist: Dr Alexander Drilon, USA 
  • Pathologist: Prof. Keith Kerr, UK
  • Radiation oncologist: Prof. Andrea Bezjak, Canada
  • Oncology nurse practitioner: Dr Marianne Davies, USA

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics,  Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.


    For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/

    12 min
  • The role of biomarker testing in NSCLC

    touchMDT for touchONCOLOGY

    Listen to a medical oncologist and a pathologist discuss the evolving role of biomarker testing in NSCLC in the light of emerging testing methodologies and treatment targets.

    The multidisciplinary team

    • Medical oncologist: Dr Alexander Drilon, USA 
  • Pathologist: Prof. Keith Kerr, UK

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics,  Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/

    12 min
  • Navigating treatment decisions in NSCLC

    Listen to a medical oncologist, a pathologist and an oncology nurse practitioner discuss the evolving treatment landscape and how treatment decisions need to take into account potential side effects.

    The multidisciplinary team

    • Medical oncologist: Dr Alexander Drilon, USA 
  • Pathologist: Prof. Keith Kerr, UK
  • Oncology nurse practitioner: Dr Marianne Davies, USA

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics,  Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/

    13 min
  • Initial assessment of NSCLC

    touchMDT for touchONCOLOGY

    Listen to a medical oncologist and a radiation oncologist discuss the importance of the initial assessment in NSCLC and the role of the different members of the multidisciplinary team.

    The multidisciplinary team

    • Medical oncologist: Dr Alexander Drilon, USA
  • Radiation oncologist: Prof. Andrea Bejzak, Canada

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics,  Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/

    12 min
  • Experts discuss the emerging role of SERDs in HR+ breast cancer

    touchPANEL DISCUSSION for touchONCOLOGY

    Listen to leading experts review the latest advances in HR+ breast cancer, focusing on the management of specific patient subgroups and the potential impact of emerging oral, second-generation SERDs on patient standard of care.

    The experts

    • Prof. Hope S Rugo – UCSF Comprehensive Cancer Center, San Francisco, CA, USA
  • Dr Fatima Cardoso – Champalimaud Clinical Center, Lisbon, Portugal
  • Dr Matti Aapro – Genolier Cancer Center, Genolier, Switzerland

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent educational grant from Sanofi Genzyme. This activity is provided by touchIME.

    For further information visit our website:  https://touchoncologyime.org/emerging-serds-for-treating-hr-positive-breast-cancer/

     

     

    35 min
  • Novel targeted therapies for NSCLC: Exploring HER2 dysregulation

    touchPANEL DISCUSSION for touchONCOLOGY

    Listen to a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC.


    The experts

    • Prof. Egbert Smit – Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
  • Dr Jarushka Naidoo – Beaumont Hospital, Dublin, Ireland
  • Dr Katerina Politi – Yale School of Medicine, New Haven, CT, US

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent educational grant from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. This activity is jointly provided by USF Health and touchIME.


    For further information visit our website: 
    https://touchoncologyime.org/her2-dysregulation-nsclc-targeted-therapy/

    34 min
  • Experts discuss non-steroidal MRAs for the treatment of patients with T2D and CKD

    touchPANEL DISCUSSION for touchENDOCRINOLOGY

    Listen to leading experts discuss why the treatment landscape for patients with T2D and CKD requires novel therapies; why non-steroidal MRAs are being investigated in these patients and the latest clinical data; and how non-steroidal MRAs might fit into the current T2D and CKD treatment paradigm.

    The experts

    • Prof. Christoph Wanner, University Hospital of Würzburg, Würzburg, Germany
  • Dr Javed Butler, University of Mississippi Medical Center, Jackson, MS, USA 
  • Prof. Janet McGill, Washington University School of Medicine, St. Louis, MO, USA

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent educational grant from Bayer. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: 

    https://touchendocrinologyime.org/non-steroidal-mras-in-the-management-of-patients-with-ckd-and-t2d

     

    38 min
  • Immunotherapy and evolving approaches for basal cell carcinoma

    touchPANEL DISCUSSION for touchONCOLOGY

    Listen to leading experts discuss evolving treatment options for patients with EGFR-mutant NSCLC, and the rationale for biomarker testing in both early-stage and metastatic disease to determine best treatment approaches, taking in recently presented data from the World Lung Cancer Congress and ESMO Congress 2021.

    The experts

    • Dr Pasi Jӓnne, Dana-Farber Cancer Institute, Boston, MA, USA
  • Dr Thanyanan Reungwetwattana, Ramathibodi Hospital, Bangkok, Thailand
  • Dr Neal Navani, University College London, London, UK

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent educational grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchoncologyime.org/deciphering-data-egfr-mutant-nsclc/

    38 min

About touchPODCAST

From the publisher's feed

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.